QTTB Q32 Bio | $18.19
-5.8% | 5/21/2024 | Initiated by | SVB Leerink | - | Outperform | $54.00 | Low | View details for SVB Leerink rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $0.74
-2.6% | 5/15/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $3.00 -> $1.00 | Low | View details for SVB Leerink rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/15/2024 |
AIRS AirSculpt Technologies | $4.01
+0.5% | 5/14/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $8.25 -> $5.00 | Low | View details for SVB Leerink rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
EHAB Enhabit | $8.68
-1.8% | 5/14/2024 | Upgraded by | SVB Leerink | - | Underperform -> Market Perform | $8.50 | Low | View details for SVB Leerink rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AQST Aquestive Therapeutics | $2.68
-1.8% | 5/10/2024 | Initiated by | SVB Leerink | - | Outperform | $8.00 | Low | View details for SVB Leerink rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $23.90
-0.5% | 5/8/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $25.00 -> $35.00 | Low | View details for SVB Leerink rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
|
BPMC Blueprint Medicines | $106.71
+2.7% | 5/6/2024 | Upgraded by | SVB Leerink | - | Underperform -> Market Perform | $50.00 -> $97.00 | Low | View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 5/6/2024 |
CVS CVS Health | $61.02
-0.1% | 5/1/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $87.00 -> $60.00 | Low | View details for SVB Leerink rating of CVS Health (NYSE:CVS) on 5/1/2024 |
LXRX Lexicon Pharmaceuticals | $1.75
+1.7% | 4/30/2024 | Initiated by | SVB Leerink | - | Outperform | $5.00 | Low | View details for SVB Leerink rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
XOMA XOMA | $22.31
-7.8% | 4/29/2024 | Initiated by | SVB Leerink | - | Outperform | $40.00 | Low | View details for SVB Leerink rating of XOMA (NASDAQ:XOMA) on 4/29/2024 |
NGNE Neurogene | $30.32
-24.2% | 4/29/2024 | Initiated by | SVB Leerink | - | Outperform | $46.00 | Low | View details for SVB Leerink rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
IMCR Immunocore | $35.94
-2.8% | 4/29/2024 | Initiated by | SVB Leerink | - | Outperform | $74.00 | Low | View details for SVB Leerink rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
CVAC CureVac | $3.25
-6.6% | 4/25/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $12.00 -> $4.00 | Low | View details for SVB Leerink rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
TNDM Tandem Diabetes Care | $42.83
-0.4% | 4/25/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $34.00 -> $45.00 | Low | View details for SVB Leerink rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
RNAC Cartesian Therapeutics | $21.76
-6.7% | 4/23/2024 | Initiated by | SVB Leerink | - | Outperform | $39.00 | Low | View details for SVB Leerink rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $22.89
-2.1% | 4/16/2024 | Initiated by | SVB Leerink | - | Outperform | $47.00 | Low | View details for SVB Leerink rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $7.32
-2.1% | 4/15/2024 | Initiated by | SVB Leerink | - | Outperform | $20.00 | Low | View details for SVB Leerink rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $18.32
-0.7% | 4/15/2024 | Initiated by | SVB Leerink | - | Outperform | $32.00 | Low | View details for SVB Leerink rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
ALPN Alpine Immune Sciences | $64.97
| 4/12/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $42.00 -> $65.00 | Low | View details for SVB Leerink rating of Alpine Immune Sciences (NASDAQ:ALPN) on 4/12/2024 |
SWAV Shockwave Medical | $334.75
| 4/8/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $361.00 -> $335.00 | Low | View details for SVB Leerink rating of Shockwave Medical (NASDAQ:SWAV) on 4/8/2024 |
ARDX Ardelyx | $5.95
-5.4% | 4/5/2024 | Initiated by | SVB Leerink | - | Outperform | $14.00 | Low | View details for SVB Leerink rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $7.87
-1.5% | 4/3/2024 | Initiated by | SVB Leerink | - | Outperform | $25.00 | Low | View details for SVB Leerink rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $78.10
+1.2% | 4/1/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $69.00 -> $110.00 | Low | View details for SVB Leerink rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $3.95
-6.4% | 3/25/2024 | Initiated by | SVB Leerink | - | Outperform | $26.00 | Low | View details for SVB Leerink rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
FUSN Fusion Pharmaceuticals | $21.55
| 3/19/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $17.00 -> $21.00 | N/A | View details for SVB Leerink rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 3/19/2024 |
WBA Walgreens Boots Alliance | $16.11
+6.3% | 3/18/2024 | Target Lowered by | SVB Leerink | - | Market Perform -> Market Perform | $23.00 -> $22.00 | Low | View details for SVB Leerink rating of Walgreens Boots Alliance (NASDAQ:WBA) on 3/18/2024 |
MIRM Mirum Pharmaceuticals | $29.25
-11.4% | 3/18/2024 | Target Lowered by | SVB Leerink | - | Outperform -> Outperform | $44.00 -> $43.00 | Low | View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 3/18/2024 |
RGLS Regulus Therapeutics | $2.48
+4.6% | 3/18/2024 | Initiated by | SVB Leerink | - | Outperform | $6.00 | Low | View details for SVB Leerink rating of Regulus Therapeutics (NASDAQ:RGLS) on 3/18/2024 |
SPRB Spruce Biosciences | $0.63
-3.1% | 3/14/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $9.00 -> $2.00 | Low | View details for SVB Leerink rating of Spruce Biosciences (NASDAQ:SPRB) on 3/14/2024 |
AMLX Amylyx Pharmaceuticals | $1.62
-1.8% | 3/11/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $12.21
+4.9% | 3/6/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $37.00 | Low | View details for SVB Leerink rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $8.08
-3.9% | 3/5/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $6.00 -> $18.00 | Low | View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $7.44
-5.7% | 3/4/2024 | Initiated by | SVB Leerink | - | Outperform | $48.00 | Low | View details for SVB Leerink rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
WBA Walgreens Boots Alliance | $16.11
+6.3% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $23.00 | Low | View details for SVB Leerink rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $25.66
| 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $42.00 | Low | View details for SVB Leerink rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
RCM R1 RCM | $12.52
+0.3% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $14.00 | Low | View details for SVB Leerink rating of R1 RCM (NASDAQ:RCM) on 2/26/2024 |
PGNY Progyny | $25.73
-3.7% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $49.00 | Low | View details for SVB Leerink rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
PINC Premier | $18.18
+0.4% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $22.50 | Low | View details for SVB Leerink rating of Premier (NASDAQ:PINC) on 2/26/2024 |
PDCO Patterson Companies | $25.38
+11.1% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $36.00 | Low | View details for SVB Leerink rating of Patterson Companies (NASDAQ:PDCO) on 2/26/2024 |
OMI Owens & Minor | $17.09
+0.6% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $24.00 | Low | View details for SVB Leerink rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
Historic NVIDIA partnership could send this tiny AI stock soaring... (Ad) After striking partnerships with trillion-dollar chipmaker NVIDIA...
ARM surged over 60% in a week... Who's next? Click here to discover the name and ticker symbol >>> |
MCK McKesson | $602.93
+0.9% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $600.00 | Low | View details for SVB Leerink rating of McKesson (NYSE:MCK) on 2/26/2024 |
LH Laboratory Co. of America | $206.49
+2.4% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $260.00 | Low | View details for SVB Leerink rating of Laboratory Co. of America (NYSE:LH) on 2/26/2024 |
IQV IQVIA | $212.93
-0.2% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $290.00 | Low | View details for SVB Leerink rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HIMS Hims & Hers Health | $24.76
+2.5% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $10.00 | Low | View details for SVB Leerink rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $8.16
-2.7% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $8.00 | Low | View details for SVB Leerink rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
NVST Envista | $16.99
-1.3% | 2/26/2024 | Initiated by | SVB Leerink | - | Underperform | $19.00 | Low | View details for SVB Leerink rating of Envista (NYSE:NVST) on 2/26/2024 |
TDOC Teladoc Health | $10.10
-0.1% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $17.00 | Low | View details for SVB Leerink rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
CVS CVS Health | $61.02
-0.1% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $88.00 | Low | View details for SVB Leerink rating of CVS Health (NYSE:CVS) on 2/26/2024 |
HSIC Henry Schein | $68.28
+3.2% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $78.00 | Low | View details for SVB Leerink rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
DGX Quest Diagnostics | $137.32
+0.2% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $135.00 | Low | View details for SVB Leerink rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
DOCS Doximity | $27.56
-1.9% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $32.00 | Low | View details for SVB Leerink rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $13.37
-7.0% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $19.00 | Low | View details for SVB Leerink rating of Certara (NASDAQ:CERT) on 2/26/2024 |
COR Cencora | $237.22
+1.1% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $261.00 | Low | View details for SVB Leerink rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $104.09
+3.1% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $125.00 | Low | View details for SVB Leerink rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
ALGN Align Technology | $242.20
-1.4% | 2/26/2024 | Initiated by | SVB Leerink | - | Market Perform | $310.00 | Low | View details for SVB Leerink rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
ACCD Accolade | $6.15
-0.6% | 2/26/2024 | Initiated by | SVB Leerink | - | Outperform | $16.00 | Low | View details for SVB Leerink rating of Accolade (NASDAQ:ACCD) on 2/26/2024 |
APLT Applied Therapeutics | $4.50
-6.8% | 2/22/2024 | Initiated by | SVB Leerink | - | Outperform | $12.00 | Low | View details for SVB Leerink rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT RAPT Therapeutics | $3.19
-3.6% | 2/21/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $42.00 -> $10.00 | Low | View details for SVB Leerink rating of RAPT Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
BTSG BrightSpring Health Services | $10.52
+1.2% | 2/20/2024 | Initiated by | SVB Leerink | - | Outperform | $15.00 | Low | View details for SVB Leerink rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
ENGN enGene | $8.36
-3.4% | 2/20/2024 | Initiated by | SVB Leerink | - | Outperform | $31.00 | Low | View details for SVB Leerink rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
SYBX Synlogic | $1.59
| 2/9/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $305.99
+0.9% | 2/7/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $324.00 -> $318.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $306.04
+3.0% | 2/5/2024 | Initiated by | SVB Leerink | - | Outperform | $330.00 | Low | View details for SVB Leerink rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
TSVT 2seventy bio | $3.89
-4.7% | 1/31/2024 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $5.00 -> $18.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 |
NPCE NeuroPace | $6.50
| 1/30/2024 | Initiated by | SVB Leerink | - | Outperform | $22.00 | Low | View details for SVB Leerink rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $13.28
+1.0% | 1/29/2024 | Initiated by | SVB Leerink | - | Outperform | $30.00 | Low | View details for SVB Leerink rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $3.42
-6.6% | 1/23/2024 | Initiated by | SVB Leerink | - | Outperform | $12.00 | Low | View details for SVB Leerink rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AXNX Axonics | $67.51
+0.3% | 1/12/2024 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $71.00 | Low | View details for SVB Leerink rating of Axonics (NASDAQ:AXNX) on 1/12/2024 |
AGL agilon health | $6.74
+1.4% | 1/8/2024 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of agilon health (NYSE:AGL) on 1/8/2024 |
ALVR AlloVir | $0.74
+1.4% | 12/22/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $5.71
-4.7% | 12/19/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $5.00 -> $12.00 | Low | View details for SVB Leerink rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
RPHM Reneo Pharmaceuticals | $1.58
-4.2% | 12/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Reneo Pharmaceuticals (NASDAQ:RPHM) on 12/15/2023 |
INCY Incyte | $61.44
-2.0% | 12/13/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $78.00 | Low | View details for SVB Leerink rating of Incyte (NASDAQ:INCY) on 12/13/2023 |
NBTX Nanobiotix | $4.54
-6.0% | 12/8/2023 | Initiated by | SVB Leerink | - | Outperform | $11.00 | Low | View details for SVB Leerink rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TNYA Tenaya Therapeutics | $3.16
-4.2% | 11/30/2023 | Initiated by | SVB Leerink | - | Outperform | $7.00 | Low | View details for SVB Leerink rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
LXEO Lexeo Therapeutics | $15.64
-3.8% | 11/28/2023 | Initiated by | SVB Leerink | - | Outperform | $19.00 | Low | View details for SVB Leerink rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $13.55
| 11/14/2023 | Initiated by | SVB Leerink | - | Outperform | $20.00 | Low | View details for SVB Leerink rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
ZNTL Zentalis Pharmaceuticals | $4.14
-50.7% | 11/7/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $15.00 | Low | View details for SVB Leerink rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $3.89
-4.7% | 10/30/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $6.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
BEAM Beam Therapeutics | $23.17
-3.6% | 10/20/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | $75.00 -> $20.00 | Low | View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
FDMT 4D Molecular Therapeutics | $22.78
-4.3% | 10/18/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $24.00 | Low | View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
AXGN AxoGen | $7.15
-3.5% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $9.00 | Low | View details for SVB Leerink rating of AxoGen (NASDAQ:AXGN) on 10/16/2023 |
AXNX Axonics | $67.51
+0.3% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $70.00 | Low | View details for SVB Leerink rating of Axonics (NASDAQ:AXNX) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $62.00
-0.1% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $37.00 | Low | View details for SVB Leerink rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
DXCM DexCom | $116.64
+0.1% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $110.00 | Low | View details for SVB Leerink rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
EW Edwards Lifesciences | $88.53
+1.9% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $75.00 | Low | View details for SVB Leerink rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
SWAV Shockwave Medical | $334.75
| 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $263.00 | Low | View details for SVB Leerink rating of Shockwave Medical (NASDAQ:SWAV) on 10/16/2023 |
INSP Inspire Medical Systems | $162.59
-0.7% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $159.00 | Low | View details for SVB Leerink rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
TNDM Tandem Diabetes Care | $42.83
-0.4% | 10/16/2023 | Initiated by | SVB Leerink | - | Market Perform | $21.00 | Low | View details for SVB Leerink rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
ISRG Intuitive Surgical | $435.00
+1.2% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $342.00 | Low | View details for SVB Leerink rating of Intuitive Surgical (NASDAQ:ISRG) on 10/16/2023 |
Kiss of death from Joe Biden (Ad) Biden cannot lose this election.
A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election. I have uncovered a bombshell that changes everything… and threatens everything. |
VCEL Vericel | $43.37
+4.0% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $42.00 | Low | View details for SVB Leerink rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
PODD Insulet | $196.40
-1.0% | 10/16/2023 | Initiated by | SVB Leerink | - | Outperform | $184.00 | Low | View details for SVB Leerink rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
AMGN Amgen | $305.99
+0.9% | 10/11/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $267.00 -> $318.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
NBIX Neurocrine Biosciences | $130.86
-3.3% | 10/6/2023 | Target Raised by | SVB Leerink | Analyst M. Goodman | | $125.00 -> $135.00 | Low | View details for SVB Leerink rating of Neurocrine Biosciences (NASDAQ:NBIX) on 10/6/2023 |
GPCR Structure Therapeutics | $47.52
-2.2% | 9/29/2023 | Target Raised by | SVB Leerink | - | | $46.00 -> $97.00 | Low | View details for SVB Leerink rating of Structure Therapeutics (NASDAQ:GPCR) on 9/29/2023 |
SPRY ARS Pharmaceuticals | $8.08
-3.9% | 9/21/2023 | Downgraded by | SVB Leerink | - | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
PTCT PTC Therapeutics | $35.62
+0.6% | 9/18/2023 | Target Lowered by | SVB Leerink | Analyst J. Schwartz | | $44.00 -> $30.00 | Low | View details for SVB Leerink rating of PTC Therapeutics (NASDAQ:PTCT) on 9/18/2023 |
SPRB Spruce Biosciences | $0.63
-3.1% | 9/8/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $3.00 -> $9.00 | Low | View details for SVB Leerink rating of Spruce Biosciences (NASDAQ:SPRB) on 9/8/2023 |
GLTO Galecto | $0.49
-2.0% | 8/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $13.00 -> $2.00 | Low | View details for SVB Leerink rating of Galecto (NASDAQ:GLTO) on 8/15/2023 |
DSGN Design Therapeutics | $3.54
-7.3% | 8/15/2023 | Reiterated by | SVB Leerink | - | Outperform -> Market Perform | $6.00 | Low | View details for SVB Leerink rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $51.94
-1.6% | 8/15/2023 | Initiated by | SVB Leerink | - | Outperform | $58.00 | Low | View details for SVB Leerink rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
EXEL Exelixis | $21.56
-1.0% | 8/8/2023 | Initiated by | SVB Leerink | - | Market Perform | $18.00 | Low | View details for SVB Leerink rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $37.27
-0.8% | 8/8/2023 | Initiated by | SVB Leerink | - | Outperform | $33.00 | Low | View details for SVB Leerink rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
NUVL Nuvalent | $78.10
+1.2% | 8/8/2023 | Initiated by | SVB Leerink | - | Market Perform | $42.00 | Low | View details for SVB Leerink rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
NVCR NovoCure | $19.44
+0.2% | 8/4/2023 | Initiated by | SVB Leerink | - | Outperform | $51.00 | Low | View details for SVB Leerink rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
BLTE Belite Bio | $49.65
+0.1% | 7/26/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $25.00 | Low | View details for SVB Leerink rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
NBIX Neurocrine Biosciences | $130.86
-3.3% | 7/24/2023 | Upgraded by | SVB Leerink | Analyst M. Goodman | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
CYRX Cryoport | $9.50
-3.0% | 7/13/2023 | Downgraded by | SVB Leerink | Analyst P. Souda | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Cryoport (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol-Myers Squibb | $40.82
-0.4% | 7/10/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Market Perform | | Low | View details for SVB Leerink rating of Bristol-Myers Squibb (NYSE:BMY) on 7/10/2023 |
EHAB Enhabit | $8.68
-1.8% | 6/20/2023 | Reiterated by | SVB Leerink | Analyst W. Mayo | Underperform | | Low | View details for SVB Leerink rating of Enhabit (NYSE:EHAB) on 6/20/2023 |
OCS Oculis | $11.75
| 6/12/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | | Low | View details for SVB Leerink rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
BPMC Blueprint Medicines | $106.71
+2.7% | 6/5/2023 | Downgraded by | SVB Leerink | Analyst A. Berens | Market Perform -> Underperform | | Low | View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 6/5/2023 |
ELEV Elevation Oncology | $2.76
-7.4% | 5/30/2023 | Upgraded by | SVB Leerink | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Elevation Oncology (NASDAQ:ELEV) on 5/30/2023 |
BOLT Bolt Biotherapeutics | $0.74
-2.6% | 5/12/2023 | Upgraded by | SVB Leerink | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/12/2023 |
ARWR Arrowhead Pharmaceuticals | $23.58
-6.1% | 5/12/2023 | Downgraded by | SVB Leerink | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
DHR Danaher | $257.44
+1.3% | 5/1/2023 | Reiterated by | SVB Leerink | Analyst P. Souda | Outperform | | Low | View details for SVB Leerink rating of Danaher (NYSE:DHR) on 5/1/2023 |
PRTA Prothena | $19.54
-4.1% | 4/24/2023 | Reiterated by | SVB Leerink | Analyst R. Li | Outperform | | Low | View details for SVB Leerink rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
GNFT Genfit | $4.18
+2.0% | 4/14/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | | Low | View details for SVB Leerink rating of Genfit (NASDAQ:GNFT) on 4/14/2023 |
CNTB Connect Biopharma | $1.49
-9.7% | 4/12/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | | Low | View details for SVB Leerink rating of Connect Biopharma (NASDAQ:CNTB) on 4/12/2023 |
ARWR Arrowhead Pharmaceuticals | $23.58
-6.1% | 4/12/2023 | Upgraded by | SVB Leerink | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $28.15
-1.5% | 4/11/2023 | Reiterated by | SVB Leerink | Analyst R. Ruiz | Market Perform | $25.00 | Low | View details for SVB Leerink rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
ACLX Arcellx | $53.81
+0.1% | 3/30/2023 | Target Raised by | SVB Leerink | - | Outperform | $35.00 -> $39.00 | Low | View details for SVB Leerink rating of Arcellx (NASDAQ:ACLX) on 3/30/2023 |
ABT Abbott Laboratories | $103.99
+0.5% | 3/31/2023 | Target Raised by | SVB Leerink | - | Market Perform | $90.00 -> $102.00 | Low | View details for SVB Leerink rating of Abbott Laboratories (NYSE:ABT) on 3/31/2023 |
REGN Regeneron Pharmaceuticals | $1,039.11
-0.6% | 3/27/2023 | Upgraded by | SVB Leerink | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for SVB Leerink rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
PTCT PTC Therapeutics | $35.62
+0.6% | 3/17/2023 | Reiterated by | SVB Leerink | Analyst J. Schwartz | Market Perform | $48.00 | Low | View details for SVB Leerink rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
CNTA Centessa Pharmaceuticals | $8.52
-10.6% | 3/17/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | $6.00 | Low | View details for SVB Leerink rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023 |
HALO Halozyme Therapeutics | $50.27
+1.2% | 3/16/2023 | Downgraded by | SVB Leerink | Analyst D. Risinger | Outperform -> Market Perform | $42.00 | Low | View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
MORF Morphic | $26.16
+0.2% | 3/8/2023 | Target Raised by | SVB Leerink | - | Outperform | $45.00 -> $56.00 | Low | View details for SVB Leerink rating of Morphic (NASDAQ:MORF) on 3/8/2023 |
ARGX argenx | $377.96
-0.1% | 3/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $430.00 -> $435.00 | Low | View details for SVB Leerink rating of argenx (NASDAQ:ARGX) on 3/3/2023 |
GPCR Structure Therapeutics | $47.52
-2.2% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | | Low | View details for SVB Leerink rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
CGEN Compugen | $1.86
-5.1% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst D. Graybosch | Outperform | | Low | View details for SVB Leerink rating of Compugen (NASDAQ:CGEN) on 2/28/2023 |
IRON Disc Medicine | $43.54
-2.9% | 2/28/2023 | Reiterated by | SVB Leerink | Analyst T. Smith | Outperform | $36.00 | Low | View details for SVB Leerink rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
XNCR Xencor | $19.44
-0.4% | 2/23/2023 | Reiterated by | SVB Leerink | Analyst J. Chang | Outperform | | Low | View details for SVB Leerink rating of Xencor (NASDAQ:XNCR) on 2/23/2023 |
MRNA Moderna | $133.27
-3.4% | 2/24/2023 | Downgraded by | SVB Leerink | Analyst M. Foroohar | Market Perform -> Underperform | $111.00 -> $93.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
NKTR Nektar Therapeutics | $1.14
-2.6% | 2/24/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $5.00 -> $3.00 | N/A | View details for SVB Leerink rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
BPMC Blueprint Medicines | $106.71
+2.7% | 2/24/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $45.00 -> $38.00 | Low | View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $40.64
-0.3% | 2/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $34.00 -> $27.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $10.10
-0.1% | 2/23/2023 | Upgraded by | SVB Leerink | Analyst S. Davis | Market Perform -> Outperform | $34.00 | Low | View details for SVB Leerink rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $171.35
+1.0% | 2/10/2023 | Upgraded by | SVB Leerink | Analyst D. Risinger | Underperform -> Market Perform | $135.00 -> $153.00 | Low | View details for SVB Leerink rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
ENTA Enanta Pharmaceuticals | $11.83
-2.0% | 2/9/2023 | Reiterated by | SVB Leerink | - | Market Perform | $49.00 | Low | View details for SVB Leerink rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 2/9/2023 |
Kiss of death from Joe Biden (Ad) Biden cannot lose this election.
A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election. I have uncovered a bombshell that changes everything… and threatens everything. |
CNTB Connect Biopharma | $1.49
-9.7% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $9.00 -> $7.00 | Low | View details for SVB Leerink rating of Connect Biopharma (NASDAQ:CNTB) on 2/8/2023 |
EQ Equillium | $0.69
-4.2% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $12.00 -> $7.00 | Low | View details for SVB Leerink rating of Equillium (NASDAQ:EQ) on 2/8/2023 |
CI The Cigna Group | $334.81
+0.3% | 2/8/2023 | Target Raised by | SVB Leerink | - | Market Perform | $309.00 -> $335.00 | Low | View details for SVB Leerink rating of The Cigna Group (NYSE:CI) on 2/8/2023 |
PINC Premier | $18.18
+0.4% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $46.00 -> $42.00 | Low | View details for SVB Leerink rating of Premier (NASDAQ:PINC) on 2/8/2023 |
ILMN Illumina | $108.10
-0.9% | 2/8/2023 | Target Raised by | SVB Leerink | Analyst P. Souda | Outperform | $249.00 -> $250.00 | Low | View details for SVB Leerink rating of Illumina (NASDAQ:ILMN) on 2/8/2023 |
VRTX Vertex Pharmaceuticals | $467.28
-1.4% | 2/8/2023 | Target Lowered by | SVB Leerink | - | Outperform | $374.00 -> $365.00 | Low | View details for SVB Leerink rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023 |
INCY Incyte | $61.44
-2.0% | 2/8/2023 | Reiterated by | SVB Leerink | - | Underperform | $63.00 | Low | View details for SVB Leerink rating of Incyte (NASDAQ:INCY) on 2/8/2023 |
DCPH Deciphera Pharmaceuticals | $25.59
| 2/7/2023 | Target Raised by | SVB Leerink | - | Outperform | $28.00 -> $30.00 | Low | View details for SVB Leerink rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 2/7/2023 |
GMAB Genmab A/S | $25.80
+0.1% | 2/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $33.00 -> $36.00 | Low | View details for SVB Leerink rating of Genmab A/S (NASDAQ:GMAB) on 2/6/2023 |
FDMT 4D Molecular Therapeutics | $22.78
-4.3% | 2/6/2023 | Target Lowered by | SVB Leerink | Analyst M. Foroohar | Market Perform | $15.00 -> $14.00 | Low | View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 2/6/2023 |
IMVT Immunovant | $26.19
-2.3% | 2/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $14.00 -> $21.00 | Low | View details for SVB Leerink rating of Immunovant (NASDAQ:IMVT) on 2/6/2023 |
REGN Regeneron Pharmaceuticals | $1,039.11
-0.6% | 2/6/2023 | Target Raised by | SVB Leerink | Analyst D. Risinger | Market Perform | $770.00 -> $834.00 | Low | View details for SVB Leerink rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/6/2023 |
GILD Gilead Sciences | $63.15
-1.7% | 2/3/2023 | Target Raised by | SVB Leerink | Analyst D. Risinger | Market Perform | $81.00 -> $91.00 | Low | View details for SVB Leerink rating of Gilead Sciences (NASDAQ:GILD) on 2/3/2023 |
TECH Bio-Techne | $74.54
-0.4% | 2/3/2023 | Target Lowered by | SVB Leerink | - | Outperform | $125.00 -> $110.00 | Low | View details for SVB Leerink rating of Bio-Techne (NASDAQ:TECH) on 2/3/2023 |
BMRN BioMarin Pharmaceutical | $84.15
-1.0% | 2/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $122.00 -> $130.00 | Low | View details for SVB Leerink rating of BioMarin Pharmaceutical (NASDAQ:BMRN) on 2/3/2023 |
IONS Ionis Pharmaceuticals | $40.64
-0.3% | 2/3/2023 | Target Raised by | SVB Leerink | - | Market Perform | $33.00 -> $34.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/3/2023 |
MRK Merck & Co., Inc. | $127.99
+0.4% | 2/3/2023 | Target Raised by | SVB Leerink | - | Outperform | $120.00 -> $122.00 | Low | View details for SVB Leerink rating of Merck & Co., Inc. (NYSE:MRK) on 2/3/2023 |
KALV KalVista Pharmaceuticals | $11.37
-3.8% | 2/3/2023 | Target Lowered by | SVB Leerink | - | Outperform | $30.00 -> $20.00 | Low | View details for SVB Leerink rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 2/3/2023 |
PHVS Pharvaris | $19.32
+3.5% | 2/3/2023 | Target Lowered by | SVB Leerink | Analyst Joseph Schwartz | Outperform | $20.00 -> $18.00 | Low | View details for SVB Leerink rating of Pharvaris (NASDAQ:PHVS) on 2/3/2023 |
TMO Thermo Fisher Scientific | $569.17
+0.2% | 2/2/2023 | Target Raised by | SVB Leerink | - | Outperform | $620.00 -> $630.00 | Low | View details for SVB Leerink rating of Thermo Fisher Scientific (NYSE:TMO) on 2/2/2023 |
HOLX Hologic | $71.47
+0.1% | 2/2/2023 | Target Raised by | SVB Leerink | - | Outperform | $90.00 -> $93.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 2/2/2023 |
AMGN Amgen | $305.99
+0.9% | 2/2/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $282.00 -> $267.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 2/2/2023 |
PFE Pfizer | $27.41
+1.6% | 2/1/2023 | Target Lowered by | SVB Leerink | Analyst David Risinger | Market Perform | $49.00 -> $48.00 | Low | View details for SVB Leerink rating of Pfizer (NYSE:PFE) on 2/1/2023 |
OPRX OptimizeRx | $10.82
-1.1% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform | | Low | View details for SVB Leerink rating of OptimizeRx (NASDAQ:OPRX) on 1/27/2023 |
OMCL Omnicell | $27.46
-1.6% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Market Perform | | Low | View details for SVB Leerink rating of Omnicell (NASDAQ:OMCL) on 1/27/2023 |
IQV IQVIA | $212.93
-0.2% | 1/27/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform | | Low | View details for SVB Leerink rating of IQVIA (NYSE:IQV) on 1/27/2023 |
DNLI Denali Therapeutics | $20.62
+0.7% | 1/30/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $50.00 | Low | View details for SVB Leerink rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023 |
AVIR Atea Pharmaceuticals | $3.49
-1.1% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $8.00 -> $6.00 | Low | View details for SVB Leerink rating of Atea Pharmaceuticals (NASDAQ:AVIR) on 1/27/2023 |
ENTA Enanta Pharmaceuticals | $11.83
-2.0% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $50.00 -> $49.00 | Low | View details for SVB Leerink rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 1/27/2023 |
SCPH scPharmaceuticals | $3.99
-2.0% | 1/27/2023 | Target Raised by | SVB Leerink | Analyst R. Ruiz | Outperform | $12.00 -> $13.00 | Low | View details for SVB Leerink rating of scPharmaceuticals (NASDAQ:SCPH) on 1/27/2023 |
VIR Vir Biotechnology | $8.95
-2.5% | 1/27/2023 | Target Lowered by | SVB Leerink | Analyst R. Ruiz | Outperform | $45.00 -> $43.00 | Low | View details for SVB Leerink rating of Vir Biotechnology (NASDAQ:VIR) on 1/27/2023 |
XERS Xeris Biopharma | $2.13
-2.3% | 1/27/2023 | Target Lowered by | SVB Leerink | - | Outperform | $6.00 -> $5.00 | Low | View details for SVB Leerink rating of Xeris Biopharma (NASDAQ:XERS) on 1/27/2023 |
ELV Elevance Health | $527.49
-1.3% | 1/26/2023 | Reiterated by | SVB Leerink | Analyst W. Mayo | Outperform | $580.00 | Low | View details for SVB Leerink rating of Elevance Health (NYSE:ELV) on 1/26/2023 |
PLRX Pliant Therapeutics | $10.71
-4.4% | 1/24/2023 | Target Raised by | SVB Leerink | - | Outperform | $33.00 -> $45.00 | Low | View details for SVB Leerink rating of Pliant Therapeutics (NASDAQ:PLRX) on 1/24/2023 |
BHVN Biohaven | $32.77
-0.7% | 1/24/2023 | Reiterated by | SVB Leerink | Analyst M. Goodman | Outperform | $24.00 | Low | View details for SVB Leerink rating of Biohaven (NYSE:BHVN) on 1/24/2023 |
MRK Merck & Co., Inc. | $127.99
+0.4% | 1/23/2023 | Target Raised by | SVB Leerink | - | Outperform | $112.00 -> $120.00 | Low | View details for SVB Leerink rating of Merck & Co., Inc. (NYSE:MRK) on 1/23/2023 |
MRNS Marinus Pharmaceuticals | $1.40
-3.5% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $27.00 -> $23.00 | Low | View details for SVB Leerink rating of Marinus Pharmaceuticals (NASDAQ:MRNS) on 1/23/2023 |
RLMD Relmada Therapeutics | $3.03
+1.0% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $42.00 -> $10.00 | Low | View details for SVB Leerink rating of Relmada Therapeutics (NASDAQ:RLMD) on 1/23/2023 |
ALNY Alnylam Pharmaceuticals | $153.86
-2.2% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $144.00 -> $143.00 | Low | View details for SVB Leerink rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/23/2023 |
ALVR AlloVir | $0.74
+1.4% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $25.00 -> $19.00 | Low | View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 1/23/2023 |
BBIO BridgeBio Pharma | $27.61
+1.4% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $23.00 -> $19.00 | Low | View details for SVB Leerink rating of BridgeBio Pharma (NASDAQ:BBIO) on 1/23/2023 |
BEAM Beam Therapeutics | $23.17
-3.6% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $81.00 -> $77.00 | Low | View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 1/23/2023 |
BLUE bluebird bio | $0.91
-4.2% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $9.00 -> $8.00 | Low | View details for SVB Leerink rating of bluebird bio (NASDAQ:BLUE) on 1/23/2023 |
EDIT Editas Medicine | $5.04
-0.6% | 1/23/2023 | Target Raised by | SVB Leerink | Analyst R. Bienkowski | Market Perform | $6.00 -> $7.00 | Low | View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 1/23/2023 |
IONS Ionis Pharmaceuticals | $40.64
-0.3% | 1/23/2023 | Target Raised by | SVB Leerink | - | Market Perform | $32.00 -> $33.00 | Low | View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 1/23/2023 |
NTLA Intellia Therapeutics | $24.80
-1.5% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $86.00 -> $84.00 | Low | View details for SVB Leerink rating of Intellia Therapeutics (NASDAQ:NTLA) on 1/23/2023 |
RCKT Rocket Pharmaceuticals | $20.68
-2.5% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Outperform | $50.00 -> $49.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 1/23/2023 |
RGNX REGENXBIO | $12.21
+4.9% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $15.00 -> $14.00 | Low | View details for SVB Leerink rating of REGENXBIO (NASDAQ:RGNX) on 1/23/2023 |
RXRX Recursion Pharmaceuticals | $9.70
+3.5% | 1/23/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $9.00 -> $8.00 | Low | View details for SVB Leerink rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 1/23/2023 |
SRPT Sarepta Therapeutics | $117.52
+0.6% | 1/20/2023 | Reiterated by | SVB Leerink | - | Outperform | $160.00 | Low | View details for SVB Leerink rating of Sarepta Therapeutics (NASDAQ:SRPT) on 1/20/2023 |
Historic NVIDIA partnership could send this tiny AI stock soaring... (Ad) After striking partnerships with trillion-dollar chipmaker NVIDIA...
ARM surged over 60% in a week... Who's next? Click here to discover the name and ticker symbol >>> |
ZYME Zymeworks | $8.52
-0.2% | 1/20/2023 | Target Raised by | SVB Leerink | Analyst A. Berens | Market Perform | $8.00 -> $10.00 | Low | View details for SVB Leerink rating of Zymeworks (NYSE:ZYME) on 1/20/2023 |
BGNE BeiGene | $154.70
-2.9% | 1/20/2023 | Target Raised by | SVB Leerink | - | Outperform | $236.00 -> $300.00 | Low | View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 1/20/2023 |
JNJ Johnson & Johnson | $145.65
-0.2% | 1/20/2023 | Target Lowered by | SVB Leerink | - | Outperform | $194.00 -> $186.00 | Low | View details for SVB Leerink rating of Johnson & Johnson (NYSE:JNJ) on 1/20/2023 |
MRNA Moderna | $133.27
-3.4% | 1/18/2023 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $102.00 -> $111.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 1/18/2023 |
EOLS Evolus | $10.64
-2.2% | 1/19/2023 | Target Raised by | SVB Leerink | - | Outperform | $18.00 -> $20.00 | Low | View details for SVB Leerink rating of Evolus (NASDAQ:EOLS) on 1/19/2023 |
VRTX Vertex Pharmaceuticals | $467.28
-1.4% | 1/17/2023 | Upgraded by | SVB Leerink | - | Market Perform -> Outperform | $374.00 | Low | View details for SVB Leerink rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/17/2023 |
EXAS Exact Sciences | $41.92
+1.4% | 1/12/2023 | Target Raised by | SVB Leerink | - | Outperform | $70.00 -> $75.00 | Low | View details for SVB Leerink rating of Exact Sciences (NASDAQ:EXAS) on 1/12/2023 |
HOLX Hologic | $71.47
+0.1% | 1/12/2023 | Target Raised by | SVB Leerink | - | Outperform | $85.00 -> $90.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 1/12/2023 |
HALO Halozyme Therapeutics | $50.27
+1.2% | 1/11/2023 | Target Lowered by | SVB Leerink | - | Outperform | $62.00 -> $61.00 | Low | View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 1/11/2023 |
MIRM Mirum Pharmaceuticals | $29.25
-11.4% | 1/10/2023 | Target Lowered by | SVB Leerink | - | Outperform | $50.00 -> $39.00 | Low | View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 1/10/2023 |
EDIT Editas Medicine | $5.04
-0.6% | 1/10/2023 | Target Lowered by | SVB Leerink | Analyst R. Bienkowski | Market Perform | $7.00 -> $6.00 | Low | View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 1/10/2023 |
KPTI Karyopharm Therapeutics | $0.93
-4.1% | 1/10/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $6.00 -> $5.00 | Low | View details for SVB Leerink rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 1/10/2023 |
TSVT 2seventy bio | $3.89
-4.7% | 1/10/2023 | Target Lowered by | SVB Leerink | - | Outperform | $41.00 -> $34.00 | Low | View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 1/10/2023 |
VRDN Viridian Therapeutics | $12.18
-0.2% | 1/9/2023 | Target Raised by | SVB Leerink | - | Outperform | $40.00 -> $45.00 | Low | View details for SVB Leerink rating of Viridian Therapeutics (NASDAQ:VRDN) on 1/9/2023 |
BLUE bluebird bio | $0.91
-4.2% | 1/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $8.00 -> $9.00 | Low | View details for SVB Leerink rating of bluebird bio (NASDAQ:BLUE) on 1/6/2023 |
EXAS Exact Sciences | $41.92
+1.4% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $60.00 -> $70.00 | Low | View details for SVB Leerink rating of Exact Sciences (NASDAQ:EXAS) on 1/6/2023 |
HOLX Hologic | $71.47
+0.1% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $78.00 -> $85.00 | Low | View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 1/6/2023 |
A Agilent Technologies | $134.85
+2.3% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $160.00 -> $170.00 | Low | View details for SVB Leerink rating of Agilent Technologies (NYSE:A) on 1/6/2023 |
ABCL AbCellera Biologics | $3.02
-1.3% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $18.00 | Low | View details for SVB Leerink rating of AbCellera Biologics (NASDAQ:ABCL) on 1/6/2023 |
MASS 908 Devices | $5.49
-3.5% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $25.00 -> $20.00 | Low | View details for SVB Leerink rating of 908 Devices (NASDAQ:MASS) on 1/6/2023 |
RGEN Repligen | $123.00
-1.1% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $230.00 -> $200.00 | Low | View details for SVB Leerink rating of Repligen (NASDAQ:RGEN) on 1/6/2023 |
TMO Thermo Fisher Scientific | $569.17
+0.2% | 1/6/2023 | Target Raised by | SVB Leerink | - | Outperform | $555.00 -> $620.00 | Low | View details for SVB Leerink rating of Thermo Fisher Scientific (NYSE:TMO) on 1/6/2023 |
WAT Waters | $294.40
+0.1% | 1/6/2023 | Target Raised by | SVB Leerink | - | Market Perform | $320.00 -> $352.00 | Low | View details for SVB Leerink rating of Waters (NYSE:WAT) on 1/6/2023 |
FATE Fate Therapeutics | $3.41
-4.5% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $62.00 -> $10.00 | N/A | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 1/6/2023 |
IPSC Century Therapeutics | $2.97
-5.7% | 1/6/2023 | Target Lowered by | SVB Leerink | - | Outperform | $20.00 -> $14.00 | Low | View details for SVB Leerink rating of Century Therapeutics (NASDAQ:IPSC) on 1/6/2023 |
AMED Amedisys | $91.63
-0.2% | 1/5/2023 | Target Lowered by | SVB Leerink | - | Market Perform | $96.00 -> $85.00 | Low | View details for SVB Leerink rating of Amedisys (NASDAQ:AMED) on 1/5/2023 |
COGT Cogent Biosciences | $8.50
-3.4% | 1/5/2023 | Target Raised by | SVB Leerink | - | Outperform | $18.00 -> $20.00 | Low | View details for SVB Leerink rating of Cogent Biosciences (NASDAQ:COGT) on 1/5/2023 |
PGNY Progyny | $25.73
-3.7% | 1/5/2023 | Reiterated by | SVB Leerink | Analyst S. Davis | Outperform -> Market Perform | $59.00 -> $34.00 | Low | View details for SVB Leerink rating of Progyny (NASDAQ:PGNY) on 1/5/2023 |
PHR Phreesia | $19.50
-0.8% | 1/5/2023 | Target Raised by | SVB Leerink | Analyst S. Davis | Outperform | $34.00 -> $39.00 | Low | View details for SVB Leerink rating of Phreesia (NYSE:PHR) on 1/5/2023 |
DCPH Deciphera Pharmaceuticals | $25.59
| 1/4/2023 | Target Raised by | SVB Leerink | - | Outperform | $25.00 -> $28.00 | Low | View details for SVB Leerink rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 1/4/2023 |
AMGN Amgen | $305.99
+0.9% | 12/22/2022 | Target Raised by | SVB Leerink | - | Market Perform | $256.00 -> $282.00 | Low | View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 12/22/2022 |
RCKT Rocket Pharmaceuticals | $20.68
-2.5% | 12/22/2022 | Target Lowered by | SVB Leerink | - | Outperform | $54.00 -> $50.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/22/2022 |
MDGL Madrigal Pharmaceuticals | $276.01
-0.3% | 12/20/2022 | Target Raised by | SVB Leerink | - | Outperform | $145.00 -> $315.00 | Low | View details for SVB Leerink rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 12/20/2022 |
NAMS NewAmsterdam Pharma | $17.11
-4.1% | 12/20/2022 | Initiated by | SVB Leerink | Analyst R. Ruiz | Outperform | $19.00 | Low | View details for SVB Leerink rating of NewAmsterdam Pharma (NASDAQ:NAMS) on 12/20/2022 |
PCVX Vaxcyte | $72.25
+0.5% | 12/16/2022 | Reiterated by | SVB Leerink | Analyst D. Risinger | Outperform | $60.00 | Low | View details for SVB Leerink rating of Vaxcyte (NASDAQ:PCVX) on 12/16/2022 |
HCA HCA Healthcare | $340.65
+1.5% | 12/16/2022 | Target Raised by | SVB Leerink | - | Outperform | $238.00 -> $286.00 | Low | View details for SVB Leerink rating of HCA Healthcare (NYSE:HCA) on 12/16/2022 |
LLY Eli Lilly and Company | $891.46
+0.7% | 12/16/2022 | Target Raised by | SVB Leerink | - | Outperform | $384.00 -> $410.00 | Low | View details for SVB Leerink rating of Eli Lilly and Company (NYSE:LLY) on 12/16/2022 |
ROIV Roivant Sciences | $10.84
+1.1% | 12/19/2022 | Target Raised by | SVB Leerink | - | Outperform | $8.00 -> $10.00 | Low | View details for SVB Leerink rating of Roivant Sciences (NASDAQ:ROIV) on 12/19/2022 |
KYMR Kymera Therapeutics | $31.20
-1.9% | 12/15/2022 | Target Raised by | SVB Leerink | Analyst M. Kratky | Market Perform | $26.00 -> $31.00 | Low | View details for SVB Leerink rating of Kymera Therapeutics (NASDAQ:KYMR) on 12/15/2022 |
WVE Wave Life Sciences | $5.71
-4.7% | 12/14/2022 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $2.00 -> $7.00 | Low | View details for SVB Leerink rating of Wave Life Sciences (NASDAQ:WVE) on 12/14/2022 |
MIRM Mirum Pharmaceuticals | $29.25
-11.4% | 12/14/2022 | Target Raised by | SVB Leerink | - | Outperform | $49.00 -> $50.00 | Low | View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 12/14/2022 |
MRNA Moderna | $133.27
-3.4% | 12/13/2022 | Target Raised by | SVB Leerink | Analyst M. Foroohar | Market Perform | $101.00 -> $102.00 | Low | View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 12/13/2022 |
NRIX Nurix Therapeutics | $18.44
+20.6% | 12/13/2022 | Target Lowered by | SVB Leerink | - | Outperform | $37.00 -> $28.00 | Low | View details for SVB Leerink rating of Nurix Therapeutics (NASDAQ:NRIX) on 12/13/2022 |
SPRY ARS Pharmaceuticals | $8.08
-3.9% | 12/13/2022 | Initiated by | SVB Leerink | Analyst Roanna Ruiz | Outperform | $14.00 | Low | View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 12/13/2022 |
FATE Fate Therapeutics | $3.41
-4.5% | 12/13/2022 | Target Lowered by | SVB Leerink | - | Outperform | $64.00 -> $62.00 | Low | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 12/13/2022 |
BGNE BeiGene | $154.70
-2.9% | 12/12/2022 | Target Raised by | SVB Leerink | - | Outperform | $210.00 -> $236.00 | Low | View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 12/12/2022 |
AFMD Affimed | $6.05
-10.2% | 12/12/2022 | Target Lowered by | SVB Leerink | - | Outperform | $100.00 -> $60.00 | Low | View details for SVB Leerink rating of Affimed (NASDAQ:AFMD) on 12/12/2022 |
DSGN Design Therapeutics | $3.54
-7.3% | 12/9/2022 | Target Lowered by | SVB Leerink | - | Outperform | $30.00 -> $22.00 | Low | View details for SVB Leerink rating of Design Therapeutics (NASDAQ:DSGN) on 12/9/2022 |
PHR Phreesia | $19.50
-0.8% | 12/9/2022 | Upgraded by | SVB Leerink | Analyst Stephanie Davis | Market Perform -> Outperform | $31.00 -> $34.00 | Low | View details for SVB Leerink rating of Phreesia (NYSE:PHR) on 12/9/2022 |
REPL Replimune Group | $7.64
-2.2% | 12/7/2022 | Target Raised by | SVB Leerink | - | Outperform | $30.00 -> $34.00 | Low | View details for SVB Leerink rating of Replimune Group (NASDAQ:REPL) on 12/7/2022 |
GOSS Gossamer Bio | $0.54
+3.8% | 12/7/2022 | Target Lowered by | SVB Leerink | - | Outperform | $15.00 -> $10.00 | Low | View details for SVB Leerink rating of Gossamer Bio (NASDAQ:GOSS) on 12/7/2022 |
RCKT Rocket Pharmaceuticals | $20.68
-2.5% | 12/6/2022 | Target Lowered by | SVB Leerink | - | Outperform | $56.00 -> $54.00 | Low | View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/6/2022 |
VEEV Veeva Systems | $178.78
-0.5% | 12/2/2022 | Target Lowered by | SVB Leerink | - | Outperform | $242.00 -> $233.00 | Low | View details for SVB Leerink rating of Veeva Systems (NYSE:VEEV) on 12/2/2022 |
NTLA Intellia Therapeutics | $24.80
-1.5% | 12/2/2022 | Target Lowered by | SVB Leerink | - | Outperform | $90.00 -> $86.00 | Low | View details for SVB Leerink rating of Intellia Therapeutics (NASDAQ:NTLA) on 12/2/2022 |
LNTH Lantheus | $81.13
-1.8% | 11/30/2022 | Initiated by | SVB Leerink | - | Outperform | | Low | View details for SVB Leerink rating of Lantheus (NASDAQ:LNTH) on 11/30/2022 |
FUSN Fusion Pharmaceuticals | $21.55
| 11/30/2022 | Initiated by | SVB Leerink | Analyst Faisal Khurshid | Outperform | $6.00 | Low | View details for SVB Leerink rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 11/30/2022 |
OABI OmniAb | $4.19
-1.6% | 11/29/2022 | Initiated by | SVB Leerink | Analyst Puneet Souda | Outperform | $6.00 | Low | View details for SVB Leerink rating of OmniAb (NASDAQ:OABI) on 11/29/2022 |
AXSM Axsome Therapeutics | $76.02
+0.0% | 11/29/2022 | Target Raised by | SVB Leerink | - | Outperform | $65.00 -> $85.00 | Low | View details for SVB Leerink rating of Axsome Therapeutics (NASDAQ:AXSM) on 11/29/2022 |
ARWR Arrowhead Pharmaceuticals | $23.58
-6.1% | 11/29/2022 | Target Lowered by | SVB Leerink | - | Market Perform | $33.00 -> $31.00 | Low | View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 11/29/2022 |
FATE Fate Therapeutics | $3.41
-4.5% | 11/24/2022 | Target Set by | SVB Leerink | - | | $64.00 | Low | View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 11/24/2022 |
